IG Genix animated logo.

At IgGenix, our mission is to develop first-in-class therapies for millions of people whose daily lives are limited by allergies. We believe we can truly change the face of allergic disease, empowering people to live life without the constant fear of a life-threatening allergic reaction.

At the intersection of biotechnology and allergy, our team begins with a deep understanding of molecular immunology thanks to our SEQ SIFTER™ antibody discovery platform. We then leverage this unique understanding to develop products intended to provide faster and more sustained clinical responses. Our first lead development candidate in food allergy, a first-in-class antibody, takes a revolutionary approach to directly address allergic disease by blocking the allergic cascade.

Clinical Pipeline

Food Allergies

Discovery

Lead Selection

IND-Enabling

Phase 1

Peanut: IGNX001

Discovery

Lead Selection

IND-Enabling

Phase 1

86%

Allergy Program #2

Discovery

Lead Selection

IND-Enabling

Phase 1

50%

Allergy Program #3

Discovery

Lead Selection

IND-Enabling

Phase 1

25%

Atopic / Autoimmune

Discovery

Lead Selection

IND-Enabling

Phase 1

Atopic Dermatitis

Discovery

Lead Selection

IND-Enabling

Phase 1

12%

The IgGenix Platform

Our single cell RNA-sequencing-based discovery platform, SEQ SIFTER™, captures extremely rare human B cells that produce IgE antibodies directly from human blood. Through our unique technology, IgGenix isolates and re- engineers fully human, high affinity, allergen-specific IgG antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their most immunodominant epitopes across the patient population, we intend to treat allergic pediatric and adult patients alike.

Scientists working in a lab.

Research

IgGenix is currently conducting research as part of an Institutional Review Board-approved observational study to create allergy therapeutics. IgGenix has discovered IgE antibodies and is conducting research across allergic diseases.

Several programs are currently in the IgGenix pipeline targeting both food and environmental allergies. Additional platform opportunities exist in other disease areas in which IgE and/or rare cells play an important role.

Food Allergies

Alpha-Gal Syndrome
Egg
Fish
Milk
Peanut
Sesame
Shellfish
Soy
Tree Nuts
Wheat

Environmental Allergies

Cat
Dog
Dust
Mold
Pollen

Publications

The IgGenix Team

Management

Jessica Grossman, M.D

Chief Executive Officer

Henry Lowman, Ph.D.

Chief Scientific Officer

Derek Croote, Ph.D.

Chief Technical Officer

Scientific Co-Founders

Stephen Quake, D. Phil.

Stanford University; Chan Zuckerberg Initiative

Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.

Harvard School of Public Health

Board of Directors

Samir Kaul

Khosla Ventures

Stephen Quake, D. Phil.

Stanford University; Chan Zuckerberg Initiative

Mattias Westman

Prosperity Capital Management

Scientific Advisory Board

Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.

Harvard School of Public Health

Hans Oettgen, M.D., Ph.D.

Harvard Medical School

Stephen Quake, D. Phil.

Stanford University; Chan Zuckerberg Initiative

Scott Smith, M.D., Ph.D.

Vanderbilt University

Dale Umetsu, M.D., Ph.D.

Stanford University; University of California, San Francisco

Jim Wells, Ph.D.

University of California, San Francisco

Investors

Careers

We are a small, innovative and passionate team working in a fast-paced environment at the forefront of allergy immunology. We have exciting opportunities for enthusiastic, self-motivated, and detail-oriented individuals to join the growing team at IgGenix. IgGenix offers competitive compensation, comprehensive benefits, equity, and the opportunity for growth.

Scroll through our list of open positions and apply today!

For more information contact us at HR@IgGenix.com.

Current Job Opportunities

IgGenix is a rapidly growing company. Please check back for available positions soon.

Contact

IgGenix, Inc
681 Gateway Blvd., Floor 4
South San Francisco, CA 94080
info@IgGenix.com